Psilocybin Therapy: What Johns Hopkins, NYU & Imperial College Research Shows | Self Growth Videos

In 2018, the FDA designated psilocybin a Breakthrough Therapy for treatment-resistant depression. In 2019, it received a second Breakthrough Therapy designation for major depressive disorder. These designations don’t mean psilocybin is approved — they mean the FDA believes the evidence is sufficiently promising to accelerate its clinical development pathway.

This is the same agency that designates cancer drugs and life-saving antibiotics. When the FDA calls something a Breakthrough Therapy, the scientific community pays attention.

The designation didn’t come from speculation. It came from a growing body of clinical research, primarily from Johns Hopkins, NYU, and Imperial College London, that has been accumulating for more than two decades — and that has produced some of the most striking results in modern psychiatric research.

What Psilocybin Is

Psilocybin is the primary psychoactive compound in over 200 species of mushrooms, most famously Psilocybe cubensis. It’s a prodrug — the body converts it to psilocin upon ingestion, which then acts primarily on serotonin receptors, particularly the 5-HT2A receptor. This is the same receptor family targeted by many conventional antidepressants, but psilocin’s mechanism of action is fundamentally different.

Where SSRIs work by gradually increasing serotonin availability over weeks of daily dosing, psilocybin produces its therapeutic effects — in current clinical trials — from one to three sessions total. Not daily for months. Three sessions.

The full history of psilocybin’s ceremonial use stretches back at least three thousand years in Mesoamerica. The Mazatec tradition preserved this knowledge until Maria Sabina shared it with R. Gordon Wasson in 1955, which eventually led to Albert Hofmann isolating and naming the compound psilocybin in 1958.

The Johns Hopkins Research

Johns Hopkins launched its psilocybin research program in the early 2000s under Roland Griffiths, who would go on to become one of the most cited researchers in the field. The early Hopkins work focused on characterizing the psilocybin experience itself — what it produces, how reliably it produces mystical-type experiences, and what its acute safety profile looks like.

The landmark 2016 study — still widely cited — administered psilocybin to 51 patients with life-threatening cancer diagnoses who had significant depression and anxiety related to their diagnosis. The results: a single high-dose psilocybin session produced large, significant decreases in depression and anxiety that persisted at six-month follow-up, with 80% of participants continuing to show clinically significant improvements. Most rated the experience among the most meaningful of their lives.

The 2020 Hopkins study moved beyond cancer patients to major depressive disorder in a broader population. Results were even more striking: 71% of participants showed a clinically significant antidepressant response after two psilocybin sessions. 54% were in remission at one-month follow-up.

To contextualize those numbers: conventional antidepressants show response rates around 40-50% in clinical trials, with remission rates typically below 35% — and that’s with patients taking medication daily for months. The Hopkins patients took two doses total.

The NYU and Memorial Sloan Kettering Work

NYU’s psilocybin research, led by Stephen Ross, ran a similar cancer-distress protocol in parallel with Hopkins. Their results were consistent: a single psilocybin session produced immediate and sustained reductions in cancer-related anxiety and depression, with 80% of participants maintaining clinical improvement at 6.5-month follow-up.

Perhaps more striking than the numbers was a qualitative finding that appears repeatedly across both the NYU and Hopkins datasets: the magnitude of therapeutic effect correlates with the intensity of mystical experience during the session. Participants who reported complete mystical experiences — a sense of unity, of the sacred, of deeply felt positive mood, of transcendence of time and space — showed the greatest and most durable improvement.

This finding is unusual in psychiatric research. The therapeutic mechanism appears to involve not just neurological changes but a specific quality of conscious experience. This is not how we typically think about drug treatments working.

Imperial College London: Imaging the Brain on Psilocybin

Imperial College London’s psychedelic research group, led by Robin Carhart-Harris, brought a different toolkit: neuroimaging. Rather than just measuring outcomes, they scanned brains during psilocybin experiences and in the weeks following.

What they found rewrote the default mode network story.

The default mode network (DMN) is a set of brain regions most active when we’re not focused on external tasks — when we’re ruminating, replaying memories, thinking about ourselves, worrying about the future. It’s the network most associated with the narrative self-sense. Hyperactivity of the DMN is consistently found in depression, anxiety, and addiction.

Psilocybin dramatically suppresses DMN activity during the session. The brain becomes more globally connected and less segregated — more regions talking to each other than usual, less activity in the circuits associated with self-referential looping. After the session, the DMN doesn’t immediately return to its prior level. The neurological reorganization persists.

Carhart-Harris has described psilocybin as producing a “reset” of abnormal DMN activity — comparable, metaphorically, to shaking a snow globe and allowing the settled patterns to rearrange themselves. The brain’s flexibility is temporarily increased, its habitual grooves loosened, creating a window in which therapeutic change becomes possible in a way that isn’t available in the usual constrained state.

What It’s Being Studied For

The clinical trials now underway include:

Major depressive disorder — the most advanced application. Multiple Phase 2 and Phase 3 trials are ongoing across the US and Europe.

Treatment-resistant depression — psilocybin’s Breakthrough Therapy designation is specifically for cases where multiple antidepressants have failed.

End-of-life anxiety — the original application, now with a substantial evidence base from Hopkins and NYU work.

Addiction — both nicotine addiction (Hopkins showed 80% abstinence at six-month follow-up, versus 35% for the best conventional nicotine replacement therapies) and alcohol use disorder.

Anorexia nervosa — early trials showing promise in a condition with one of the highest mortality rates in psychiatry.

OCD, PTSD, eating disorders — all in various stages of clinical investigation.

What It Isn’t

Psilocybin is not a simple antidepressant that happens to come from mushrooms. The current evidence suggests it works because of the conscious experience it produces, in combination with professional therapeutic support before and after the session. The trials showing dramatic results involve carefully structured preparation sessions, a specially trained therapist present throughout the experience, and integration therapy afterward.

Psilocybin without that context — without careful preparation, without supportive presence, without integration — produces different outcomes. The molecule isn’t the whole story. Set, setting, and support are what convert a psychedelic experience into a therapeutic one.

This is one reason the retreat industry, however valuable, isn’t equivalent to clinical treatment. It’s also why the most careful voices in this field argue against the oversimplification of psilocybin as “a pill for depression.” It’s a tool with a specific usage context that matters enormously.

The Legal Path Forward

Oregon became the first state to legalize supervised psilocybin services for adults in 2020. Colorado followed in 2022. A small but growing number of licensed facilitators are now operating legal psilocybin sessions in Oregon. The FDA’s Breakthrough designation means federal approval may follow if the Phase 3 trials currently underway produce consistent results.

Where to find access today: our psilocybin retreat centers guide covers legal options in Oregon, Colorado, Jamaica, and the Netherlands.

Related:

• Psilocybin Mushroom History: From the Mazatec to the Modern Renaissance
• Psilocybin Retreat Centers: Where Guided Mushroom Therapy Is Legal in 2026
• Maria Sabina: The Mazatec Healer Who Gave Psilocybin to the World
• Plant Medicine for Veterans: Psilocybin, Ibogaine & MDMA for PTSD
• The Full Psilocybin Guide: What It Is and How It Works